Insulin Resistance Syndrome and Glucose Dysregulation in the Elderly

Clinics in Geriatric Medicine

Volumn 24, Issue 3, 2008, Pages 437-454

  Mazza, Angela D ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; EXENDIN 4; GLUCOSE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ADIPOCYTE; ANOREXIA; BLOATING; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DRUG HALF LIFE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HIP FRACTURE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGONADISM; INCIDENCE; INSULIN RESISTANCE; LONG TERM CARE; LOOSE FECES; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NONHUMAN; OBESITY; OSTEOLYSIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT REDUCTION;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; METABOLIC SYNDROME X;

EID: 47849129466     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2008.03.006     Document Type: Review

References (104)

1. Morley J.E. Diabetes mellitus: a major disease of older persons. J Gerontol A Biol Sci Med Sci 55 (2000) M255-M256
2. Zarowitz B.J., Tangalos E.G., Hollenack K., et al. The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. J Am Med Dir Assoc 7 (2006) 234-240
3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 29 (2006) 59-42
4. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 2002. Diabetes Care 26 (2003) 917-932
5. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
6. Johnson C.L., Rifkind B.M., Sempos C.T., et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 269 (1993) 3002-3008
7. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21 (1998) 518-524
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
9. Saydah S. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes mellitus. JAMA 291 (2004) 335-342
10. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
11. Alberti K.G., and Zimmer P.Z. Definition, diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
12. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal. Diabetes Care 28 (2005) 2289-2304
13. Jeppesen J., Hansen T.W., Rasmussen S., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 49 (2007) 2112-2119
14. Nilsson G., Hedberg P., Jonason T., et al. Heart rate recovery is more strongly associated with the metabolic syndrome, waist circumference, and insulin sensitivity in women than in men among the elderly in the general population. Am Heart J 154 (2007) 460.e1-460.e7
15. Barzilay J.I., Blaum C., Moore T., et al. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med 167 (2007) 635-641
16. Vogelzangs N., Beekman A.T., Kritchevsky S.B., et al. Psychosocial risk factors and the metabolic syndrome in elderly persons: finding from the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 62 (2007) 563-569
17. Jackson R.A. Mechanisms of age-related glucose intolerance. Diabetes Care 13 Suppl 2 (1990) 9-19
18. De Rekeneire N., Peila R., Ding J., et al. Diabetes, hyperglycemia, and inflammation in older individuals. Diabetes Care 29 (2006) 1902-1907
19. Beck-Nielsen H., and Groop L.C. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 94 (1994) 1714-1721
20. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
21. Petersen K.F., Befroy D., Dufour S., et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300 (2003) 1140-1142
22. Figaro M.K., Kritchevsky S.B., Resnick H.E., et al. Diabetes, inflammation, and function decline in older adults. Diabetes Care 29 (2006) 2039-2045
23. Banks W.E., Altmann J., Sapolsky R.M., et al. Serum leptin levels as a marker for a syndrome X-like condition in wild baboons. J Clin Endocrinol Metab 88 (2003) 1234-1240
24. Jacob S., Machann J., Rett K., et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring on type 2 diabetic subjects. Diabetes 48 (1999) 1113-1119
25. Stefan N., Machann J., Schick F., et al. New imaging techniques of fat, muscle and liver within the context of determining insulin sensitivity. Horm Res 64 Suppl 3 (2005) 38-44
26. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004) 2548-2556
27. Berg A.H., Combs T.P., Du X., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
28. Combs T.P., Wagner J.A., Berger J., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
29. Orchard T.J., Temprosa M., Goldberg R., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
30. Diabetes Prevention Program Research Groups. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
31. Tuomilehto J., Lindström J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
32. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
33. American Diabetes Association. Evidence-based nutrition principles and recommendation for the treatment and prevention of diabetes and related complication. Diabetes Care 25 (2002) 202-212
34. American Diabetes Association. Nutrition recommendations and interventions for diabetes-2006. Diabetes Care 29 (2006) 2140-2157
35. Morley J.E., Kim M.J., Haren M.T., et al. Frailty and the aging male. Aging Male 8 (2005) 135-140
36. MacIntosh C., Morley J.E., and Chapman I.M. The anorexia of aging. Nutrition 16 (2000) 983-995
37. Morley J.E. Weight loss in the nursing home. J Am Med Dir Assoc 8 (2007) 201-204
38. Ensrud K.E., Ewing S.K., Taylor B.C., et al. Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 7 (2007) 744-751
39. Tariq S.H., Karcic E., Thomas D.R., et al. The use of no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Diet Assoc 101 (2001) 1463-1466
40. Coulston A.M., Mandelbaum D., and Reaven G.M. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 51 (1990) 67-71
41. Wedick N.M., Barrett-Connor E., Knoke J.D., et al. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo Study. J Am Geriatr Soc 50 (2002) 1810-1815
42. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 30 Suppl 1 (2007) S48-S65
43. DeFillipis A.P., and Sperling L.S. Understanding omega-3's. Am Heart J 151 (2006) 564-570
44. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105 (2002) 1897-1903
45. Albert C.M., Campos H., Stamper M.J., et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346 (2002) 1113-1118
46. Rivellese A., Maffettone A., Iovine C., et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 19 (1996) 1207-1211
47. Montori V.M., Farmer A., Wollan P.C., et al. Fish oil supplementation in type 2 diabetes. Diabetes Care 23 (2000) 1407-1415
48. Friedberg C., Janssen M.J., Heine R.J., et al. Fish oil and glycemic control in diabetes. Diabetes Care 21 (1998) 494-500
49. Trichopoulou A., Orfanos P., Norat T., and EPIC-Elderly Prospective Study Group. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ 330 (2005) 991-995
50. Riserus U., and Ingelsson E. Alcohol intake, insulin resistance, and abdominal obesity in elderly men. Obesity 15 (2007) 1766-1773
51. Sigal R.J., Kenny G.P., Wasserman D.H., et al. Physical activity/exercise and type 2 diabetes. Diabetes Care 27 (2004) 2518-2537
52. Castaneda C., Layne J.E., Munoz-Orians L., et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 25 (2002) 2335-2341
53. Dunstan D.W., Daly R.M., Owen N., et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 25 (2002) 1729-1736
54. Kodama S., Shu M., Murakami H., et al. Even low-intensity and low-volume exercise training may improve insulin resistance in the elderly. Intern Med 46 (2007) 1071-1077
55. Lee A., and Morley J.E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6 (1998) 47-53
56. Morley J.E., and Flood J.F. Effect of competitive antagonism of NO synthetase on weight and food intake in obese and diabetic mice. Am J Physiol 266 1 Pt 2 (1994) R164-R168
57. Kumar V.B., Bernardo A.E., Vyas K., et al. Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice. Life Sci 69 (2001) 2789-2799
58. Dornshorst A. Insulinotropic meglitnide analogues. Lancet 358 (2001) 1709-1716
59. Mazza A.D., and Morley J.E. Metabolic syndrome in the older male population. Aging Male 10 (2007) 3-8
60. Banks W.A., Willoughby L.M., Thomas D.R., et al. Insulin resistance syndrome in the elderly: assessment of functional, biochemical, metabolic, and inflammatory status. Diabetes Care 29 (2007) 2369-2373
61. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglisb:last-page>tazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368 (2006) 1096-1105
62. Marfella R., D'Amico M., Di Filippo C., et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol 47 (2006) 2444-2455
63. Cicero D.G., D'Angelo A., Gaddi A., et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 28 (2006) 679-688
64. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19 (2007) 129-137
65. Crosson J.T., Majika S.M., Grazia T., et al. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest 116 (2006) 3220-3228
66. Schwartz A.V., Sellmeyer D.E., Vittinghoff E., et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91 (2006) 3349-3354
67. Nissen N.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
68. Home P.D., Pocock S.T., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
69. Meneilly G.S., Ryan E.A., Radziuk J., et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 23 (2000) 1162-1167
70. Josse R.G., Chiasson J.L., Ryan E.A., et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 59 (2003) 37-42
71. Lee A., Patrick P., Wishart J., et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4 (2002) 329-335
72. DeLeon M.J., Chandurkar V., Albert S.G., et al. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 56 (2002) 101-106
73. Gentilcore D., Bryant B., Wishart J.M., et al. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med 118 (2005) 1289
74. Morley J.E. Editorial: postprandial hypotension-the ultimate Big Mac attack. J Gerontol A Biol Sci Med Sci 56 (2001) M741-M743
75. Shibao C., Gamboa A., Diedrich A., et al. Acarbose, an α-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension 50 (2007) 54-61
76. Nauck M.A., Niedereichholz U., Ettler R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273 (1997) 981-988
77. Hvidberg A., Nielsen M.T., Hilsted J., et al. Effect of glucagon-like peptide 1 (proglucagon 78-107 amide) on hepatic glucose production in healthy men. Metabolism 43 (1994) 104-108
78. Kaji M., Nomura M., Tamura Y., et al. Relationships between insulin resistance, blood glucose levels and gastric motility: an electrogastrography and external ultrasonography study. J Med Invest 54 (2007) 168-176
79. Tang-Christensen M., Larsen P.J., Goke R., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271 (1996) 848-856
80. Flint A., Raben A., Astrup A., et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
81. Meneilly G.S., Veldhuis J.D., and Elahi D. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes. J Clin Endocrinol Metab 90 (2004) 6251-6256
82. Egan J.M., Clocquet A.R., and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 1282-1290
83. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117 (2004) 77-88
84. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
85. Buse J.B., Henry R.R., Han J., et al., Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
86. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
87. Kim D., MacDonell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30 (2006) 1487-1493
88. Ahren B., Simonsson E., Larsson H., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
89. Vella A., Bock G., Giesler P.D., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56 (2007) 1475-1480
90. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 141-151
91. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharmacol Ther 78 (2005) 675-688
92. Nauck M.A., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9 (2007) 194-205
93. Strotmeyer E.S., Cauley J.A., Schwartz A.V., et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165 (2005) 1612-1617
94. Nicodemus K.K., and Folsom A.R. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24 (2001) 1192-1197
95. Taylor B.C., Schreiner P.J., Stone K.L., et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 52 (2004) 1479-1486
96. Dobnig H., Piswanger-Solkner J.C., Roth M., et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 91 (2006) 3355-3363
97. de Liefde I.I., van der Klift M., de Laet C.E., et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16 (2005) 1713-1720
98. Rodriguez A., Muller D.C., Metter E.J., et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92 (2007) 3568-3578
99. Travison T.G., Morley J.E., Araujo A.B., et al. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 91 (2005) 2509-2513
100. Kapoor D., Aldred H., clark S., et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care 30 (2007) 911-917
101. Tsai E.C., Matsumoto A.M., Fujimoto W.Y., et al. Association of bioavailable, free, and total testosterone with insulin resistance. Diabetes Care 27 (2004) 861-868
102. Basaria S., Muller D.C., Carducci M.A., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 (2006) 581-588
103. Fukui M., Kitagawa Y., Nakamura N., et al. Association between serum testosterone concentration in men with type 2 diabetes. Diabetes Care 26 (2003) 1869-1873
104. Kapoor D., Goodwin E., Channer K.S., et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154 (2006) 899-906